TSCAClinical Trials•businesswire•
Tasca Therapeutics Doses First Patient in Phase 1/2 Dose Escalation and Expansion Trial Evaluating CP-383 in Advanced Solid Tumors
Sentiment:Positive (65)
Summary
(TSCA) CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ClinicalTrials--Tasca Therapeutics has dosed the first patient in its Phase 1/2 dose escalation and expansion study of CP-383 in advanced solid tumors.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 16, 2025 by businesswire